Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
Publish date: September 10, 2019 By Lee S. Cohen, MD The last decade has brought increasing awareness of the need to effectively screen for postpartum depression, with a majority of states across the country now having [...]
It has been a few months since Zulresso (brexanolone), the new FDA-approved treatment for postpartum depression, has been available. At our clinic, we have had multiple queries regarding how to obtain treatment with Zulresso. One [...]
Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Since that time, Sage Therapeutics [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Since that time, Sage Therapeutics [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors. We saw the preliminary [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially [...]
